401 related articles for article (PubMed ID: 37143270)
1. Traditional and Innovative Anti-seizure Medications Targeting Key Physiopathological Mechanisms: Focus on Neurodevelopment and Neurodegeneration.
Sciaccaluga M; Ruffolo G; Palma E; Costa C
Curr Neuropharmacol; 2023; 21(8):1736-1754. PubMed ID: 37143270
[TBL] [Abstract][Full Text] [Related]
2. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy.
Löscher W
Epilepsy Res; 2002 Jun; 50(1-2):105-23. PubMed ID: 12151122
[TBL] [Abstract][Full Text] [Related]
3. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam.
Klitgaard H; Pitkänen A
Epileptic Disord; 2003 May; 5 Suppl 1():S9-16. PubMed ID: 12915336
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
Löscher W; Klein P
CNS Drugs; 2021 Sep; 35(9):935-963. PubMed ID: 34145528
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies.
Łukawski K; Andres-Mach M; Czuczwar M; Łuszczki JJ; Kruszyński K; Czuczwar SJ
Pharmacol Rep; 2018 Apr; 70(2):284-293. PubMed ID: 29477036
[TBL] [Abstract][Full Text] [Related]
7. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments.
Löscher W
Neuropharmacology; 2020 May; 167():107605. PubMed ID: 30980836
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
9. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.
Löscher W; Brandt C
Pharmacol Rev; 2010 Dec; 62(4):668-700. PubMed ID: 21079040
[TBL] [Abstract][Full Text] [Related]
10. Approach to the Medical Treatment of Epilepsy.
Brigo F; Marson A
Continuum (Minneap Minn); 2022 Apr; 28(2):483-499. PubMed ID: 35393967
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis?
Vezzani A
Expert Opin Drug Saf; 2015 Apr; 14(4):583-92. PubMed ID: 25645535
[TBL] [Abstract][Full Text] [Related]
12. Anti-seizure medications and estradiol for neuroprotection in epilepsy: the 2013 update.
Velisek L; Nebieridze N; Chachua T; Veliskova J
Recent Pat CNS Drug Discov; 2013 Apr; 8(1):24-41. PubMed ID: 23477307
[TBL] [Abstract][Full Text] [Related]
13. Epilepsy: key experimental therapeutics in early clinical development.
Steriade C; French J; Devinsky O
Expert Opin Investig Drugs; 2020 Apr; 29(4):373-383. PubMed ID: 32172604
[No Abstract] [Full Text] [Related]
14. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
15. mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment.
Ravizza T; Scheper M; Di Sapia R; Gorter J; Aronica E; Vezzani A
Nat Rev Neurosci; 2024 May; 25(5):334-350. PubMed ID: 38531962
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation.
Terrone G; Salamone A; Vezzani A
Curr Pharm Des; 2017; 23(37):5569-5576. PubMed ID: 28950818
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of currently used antiseizure drugs.
Sills GJ; Rogawski MA
Neuropharmacology; 2020 May; 168():107966. PubMed ID: 32120063
[TBL] [Abstract][Full Text] [Related]
18. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
Barker-Haliski M; Steve White H
Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
[TBL] [Abstract][Full Text] [Related]
19. Drug-mediated neuroprotection and antiepileptogenesis: animal data.
Pitkänen A
Neurology; 2002 Nov; 59(9 Suppl 5):S27-33. PubMed ID: 12428029
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures.
Reddy DS; Mbilinyi RH; Ramakrishnan S
Exp Neurol; 2023 Jan; 359():114240. PubMed ID: 36216124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
